- Previous Close
252.85 - Open
253.80 - Bid 255.60 x --
- Ask 255.70 x --
- Day's Range
252.50 - 255.90 - 52 Week Range
213.00 - 288.20 - Volume
69,671 - Avg. Volume
139,380 - Market Cap (intraday)
207.482B - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
19.30 - EPS (TTM)
13.25 - Earnings Date Jan 30, 2025
- Forward Dividend & Yield 9.60 (3.80%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
--
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
www.roche.com103,605
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ROGZ.XC
View MorePerformance Overview: ROGZ.XC
Trailing total returns as of 12/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ROGZ.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ROGZ.XC
View MoreValuation Measures
Market Cap
203.35B
Enterprise Value
228.97B
Trailing P/E
19.10
Forward P/E
12.02
PEG Ratio (5yr expected)
1.07
Price/Sales (ttm)
3.35
Price/Book (mrq)
6.96
Enterprise Value/Revenue
3.78
Enterprise Value/EBITDA
12.93
Financial Highlights
Profitability and Income Statement
Profit Margin
17.53%
Return on Assets (ttm)
12.49%
Return on Equity (ttm)
36.36%
Revenue (ttm)
60.58B
Net Income Avi to Common (ttm)
10.62B
Diluted EPS (ttm)
13.25
Balance Sheet and Cash Flow
Total Cash (mrq)
8.81B
Total Debt/Equity (mrq)
110.04%
Levered Free Cash Flow (ttm)
8.13B